BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lastraioli E, Lottini T, Iorio J, Freschi G, Fazi M, Duranti C, Carraresi L, Messerini L, Taddei A, Ringressi MN, Salemme M, Villanacci V, Vindigni C, Tomezzoli A, La Mendola R, Bencivenga M, Compagnoni B, Chiudinelli M, Saragoni L, Manzi I, De Manzoni G, Bechi P, Boni L, Arcangeli A. hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget. 2016;7:59535-59547. [PMID: 27517748 DOI: 10.18632/oncotarget.11149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Iorio J, Petroni G, Duranti C, Lastraioli E. Potassium and Sodium Channels and the Warburg Effect: Biophysical Regulation of Cancer Metabolism. Bioelectricity 2019;1:188-200. [PMID: 34471821 DOI: 10.1089/bioe.2019.0017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Anderson KJ, Cormier RT, Scott PM. Role of ion channels in gastrointestinal cancer. World J Gastroenterol 2019; 25(38): 5732-5772 [PMID: 31636470 DOI: 10.3748/wjg.v25.i38.5732] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 42] [Article Influence: 14.7] [Reference Citation Analysis]
3 Janmaat VT, van Olphen SH, Biermann KE, Looijenga LHJ, Bruno MB, Spaander MCW. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis. PLoS One 2017;12:e0186305. [PMID: 29059206 DOI: 10.1371/journal.pone.0186305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
4 Becskeházi E, Korsós MM, Erőss B, Hegyi P, Venglovecz V. OEsophageal Ion Transport Mechanisms and Significance Under Pathological Conditions. Front Physiol 2020;11:855. [PMID: 32765303 DOI: 10.3389/fphys.2020.00855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lastraioli E, Romoli MR, Iorio J, Lottini T, Chiudinelli M, Bencivenga M, Vindigni C, Tomezzoli A, De Manzoni G, Compagnoni B, Manzi I, Messerini L, Saragoni L, Arcangeli A; Gruppo Italiano di Ricerca Cancro Gastrico (GIRCG). The hERG1 Potassium Channel Behaves As Prognostic Factor In Gastric Dysplasia Endoscopic Samples. Onco Targets Ther 2019;12:9377-84. [PMID: 31807018 DOI: 10.2147/OTT.S226257] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Stock C. How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer. Rev Physiol Biochem Pharmacol 2020. [PMID: 32875386 DOI: 10.1007/112_2020_41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Duranti C, Arcangeli A. Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis. Antibodies (Basel) 2019;8:E33. [PMID: 31544839 DOI: 10.3390/antib8020033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
8 Iorio J, Meattini I, Bianchi S, Bernini M, Maragna V, Dominici L, Casella D, Vezzosi V, Orzalesi L, Nori J, Livi L, Arcangeli A, Lastraioli E. hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer. Cancer Cell Int 2018;18:93. [PMID: 30002601 DOI: 10.1186/s12935-018-0592-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Duranti C, Carraresi L, Sette A, Stefanini M, Lottini T, Crescioli S, Crociani O, Iamele L, De Jonge H, Gherardi E, Arcangeli A. Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging. Oncotarget 2018;9:34972-89. [PMID: 30405887 DOI: 10.18632/oncotarget.26200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]